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Tumour stroma ratio (TSR) is emerging as an important prognostic indicator in cancer. We have previously shown
TSR to be prognostic in oestrogen receptor positive breast cancer. Its role in inflammatory breast cancer, a rare but
aggressive form of breast cancer, has not been identified. Here we aimed to determine the prognostic significance
of TSR in a cohort of patients with inflammatory breast carcinoma.
TSR was measured by point counting virtual H&E stained tissue sections in 45 inflammatory breast cancer cases.
The whole tumour area was sampled. Optimum cut-offs to distinguish high and low TSR was determined by
log-rank test. The relationship of TSR to overall survival and disease-free survival (DFS) was analysed alongside
multivariate analysis.
The optimal cut-offs between high and low TSR were determined to be 31% for OS and 46% for DFS. There was no
significant difference in OS (p = 0.53) nor DFS (p = 0.66) between high and low TSR groups. Multivariate analysis did not
demonstrate any new trends, within the limits of a small data sample. A significant correlation was found between
pathological response to neoadjuvant chemotherapy and survival (p = 0.008).
There is no evidence that TSR has prognostic significance in inflammatory breast cancer. When compared with
published data in non-inflammatory breast carcinoma, this supports the view that differences in stromal biology exist
between tumour types and highlights the importance of considering this when interpreting the prognostic value of
TSR. However, these findings must be interpreted in the light of the small sample size.
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Tumour-stromal ratio (TSR) is fast emerging as a signifi-
cant prognostic indicator in cancer. The importance of
TSR has been investigated in cancers including prostate
(Yanagisawa et al. 2007), colorectal (West et al. 2010),
oesophageal (Wang et al. 2012) and breast (de Kruijf et al.
2011) although results so far have been inconsistent.
Breast cancer is the most common cancer in the
United Kingdom and the second most common cause of
death from cancer in women after lung cancer (Office
for National Statistics 2013). The vast heterogeneity
of the disease necessitates multiple treatment options.
Inflammatory breast cancer (IBC) is diagnosed clinically
and it is characterized by rapid onset of diffuse erythema
and warmth and oedema of the skin of the breast (peau* Correspondence: Abeer.Shaaban@uhb.nhs.uk
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in any medium, provided the original work is pd’orange). It is thought that emboli in lymphatic vessels
cause their obstruction and prevents proper drainage
of the lymph fluid thus causing swelling of the breast
and its inflammatory-like appearance (Robertson et al.
2010). In 2011, an international panel published consen-
sus criteria for the diagnosis of IBC (Dawood et al.
2011). More recently, a UK perspective on the diagnostic
criteria, management, documentation and research di-
rections has been proposed (Rea et al., Br J Cancer, in
press).
Previous studies into TSR in breast cancer have largely
focussed on hormone status, particularly triple-negative;
that is, negative for ER, PR and HER2. Moorman et al.
showed that a high percentage of stroma predicts poor
survival in triple-negative breast cancers (Moorman
et al. 2012). TSR was found to be an independent prog-
nostic factor for relapse-free survival in breast cancer
patients, and especially in those with triple-negative
disease (de Kruijf et al. 2011). However, a study ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Clinicopathological details of cohort
Characteristic (total = 45)






















≤20 mm 14 (31%)
>20 mm 29 (64%)
n/a 2 (4%)
Table 2 Median OS and DFS between TSR groups
Median survival High TSR Low TSR
OS 75 35
DFS 57.5 37
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predict survival on multivariate analysis (Ahn et al.
2012). In addition, our previous study of ER-positive
breast cancers demonstrated that a high TSR was related
to worse survival across both genders (Downey et al.
2014). The prognostic role of TSR in inflammatory
breast carcinoma has not been previously studied.
Here we aim to determine the prognostic significance
of TSR in inflammatory breast cancer. The results will




Ethical approval for the study was granted by Leeds
(East) Research Ethics Committee (Reference no: 06/
Q1206/180).
Ethical standards
All the work detailed herein was performed to comply
with the current laws of the United Kingdom.
Patients
Patients with the diagnosis of inflammatory breast can-
cer between the period 2005–2013 were identified from
the clinical database at the Leeds Teaching Hospitals
NHS Trust. H&E slides and paraffin-embedded tumour
blocks of the original (pre-treatment) core biopsy were
retrieved from the pathology archives. Comprehensive
histological and clinical data including response to
chemotherapy (complete, partial, minimal or no re-
sponse), disease-free survival and overall survival were
collected on those patients.
Clinicopathological data
Histopathological data was obtained from pathology da-
tabases. Relapse-free survival and overall survival was
available for each patient.
Measurement of stromal density
Four μm thick haematoxylin and eosin-stained tissue
sections were prepared according to standard proto-
cols. Each slide was scanned at 20× magnification with
an automated scanning system (Aperio XT, Aperio
Technologies, Vista, CA, USA). Using a digital slide
viewer (ImageScope version 8.0, Aperio Technologies),
the whole area was selected for analysis. A grid with a
systematic random sample of 300 points was then
superimposed on the selected area using virtual grati-
cule software (Treanor et al. 2008). The number of
measurement points was consistent with that found
accurate by previous studies (West et al. 2010). The
histopathological category under each point was re-
corded and the number of points attributable to eachcategory was counted. Categories used were tumour,
stroma and non-informative (unclassifiable). Points
falling on areas of lumen, necrosis, blood vessels, in-
flammation or blank areas fell into the latter category.
TSR was expressed as a percentage of all the inform-
ative points per section.
Statistical analyses
Statistical analysis was performed using GraphPad Prism
version 6, R version 2.15 and the Survival package for R.
The optimal cut-off value for TSR was calculated as fol-
lows: for each tumour proportion-value occurring in the
data set, a log-rank test was performed based on a com-
parison of the group of patients with a TSR ≤ that value,
and the patients with P above that. Primary endpoints
Figure 1 Kaplan-Meier survival curves showing overall survival after stratification by TSR.
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Univariate survival analyses were performed using
Kaplan-Meier curves. Differences between the groups
were assessed using the log-rank test. P-values of < 0.05
were considered to be statistically significant. Multivari-
ate analysis was performed using Cox’s Proportional
Hazards model.
Results
A total of 45 patients with available tumour slides/blocks
were identified. The mean age at diagnosis was 55 years
(+/− 12.8 years, range 32–84 years).
Histopathological data obtained from pathology data-
bases is summarised in Table 1. The majority of the tu-
mours were of ductal no special type, node positive,
hormone receptor and HER2 negative.
In order to determine optimum cut-offs to distinguish
high and low TSR, log-rank tests were performed to
compare groups of patients with TSR below or equal to
that value, with patients with TSR above that. The cut-Figure 2 Kaplan-Meier survival curves showing disease-free survival aoff values that led to the smallest p-value were 0.31 for
OS and 0.46 for DFS.
Median overall survival was 75 months in the high
TSR group and 35 months in the low TSR group. A
similar pattern was seen with the disease-free survival:
57.5 months in the high TSR group compared to
37 months in the low TSR group (Table 2).
There was no significant difference in survival be-
tween high and low TSR groups. This was true for both
OS (p = 0.53, Figure 1) and DFS (p = 0.66, Figure 2).
Multivariate analysis demonstrated that pathological
response (minimal or no response versus partial/
complete response) correlated with survival (p = 0.008)
but TSR was not an independent prognostic factor for
survival.
Discussion
The role of stromal microenvironment in dictating
tumour behaviour has recently been emphasised. The ini-
tiation, growth and progression of cancer is dependent onfter stratification by TSR.
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an integral part. Recently attention has focused on the po-
tential prognostic value of TSR in different types of cancer.
In general, low TSR appears to be associated with worse
prognosis; in breast (de Kruijf et al. 2011); (Moorman
et al. 2012); (Ahn et al. 2012); lung (Maeshima et al. 2002);
prostate (Yanagisawa et al. 2007); stomach (Wu et al.
2013)and colon and rectum (West et al. 2010); (Mesker
et al. 2007).
Current literature describes conflicting results, espe-
cially in breast, and seemingly dependent on hormone
status. Whereas a number of studies on triple-negative
breast cancers have found TSR to predict poor survival
(de Kruijf et al. 2011; Moorman et al. 2012; Dekker
et al. 2013), this prognostic value is diminished in
studies of unselected breast cancers (Ahn et al. 2012).
A study of ER-positive breast cancers demonstrated
that a high TSR was related to worse survival across
both genders (Downey et al. 2014) suggesting that the
importance of TSR in breast cancer may be dependent
on key molecular determinants of tumour subtype.
This is the first study to analyse stromal density and
its relation to prognosis in inflammatory breast cancer.
Our findings provide no evidence of any prognostic sig-
nificance of TSR in inflammatory breast cancer. This
finding adds to the literature base.
There are a number of methodological issues in this
study. While there was a difference in survival between
high and low TSR (75 months versus 35 months) sug-
gestive of better outcome in the high stromal group, this
did not reach statistical significance. Although 45 cases
represent a relatively large cohort in this rare disease,
the number of cases is small and the study is likely to be
underpowered. The results need to be interpreted in this
context.
Our findings suggest that differences in stromal biol-
ogy may exist between tumour subtypes and highlights
the importance of tumour subtype when interpreting the
prognostic value of TSR. Future studies may elucidate
crucial stromal differences between tumour subtypes
which could better predict survival.Competing interests
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